Another Cancer Treatment Startup for Merck

Merck & Co., Inc. (NYSE: MRK) has been busy this year. After securing a licensing deal with  Cocrystal (NASDAQ: COCP) for proprietary influenza A/B antiviral agents in January, the company found two biotechnology start-ups to bolster its cancer treatment portfolio. First, in February Merck bought Immune Design for $5.85 per share in cash, for an approximate value of […]

Merck Buys Immunotherapy Firm Immune Design

Merck & Co., Inc. (NYSE: MRK), the global healthcare and pharmaceutical company, has acquired Immune Design (NASDAQ: IMDZ) for $300 million. Merck will buy all outstanding shares of Immune Design at a value of $5.85 per share. With reported revenue of only $2 million, Immune Design’s price tag equals close to a 136x EBITDA multiple. Out of […]